{"name":"Canadian Cancer Trials Group","slug":"canadian-cancer-trials-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"ADT","genericName":"ADT","slug":"adt","indication":"Advanced prostate cancer","status":"phase_3"},{"name":"BA3021","genericName":"BA3021","slug":"ba3021","indication":"Relapsed or refractory acute myeloid leukemia","status":"phase_2"},{"name":"Folfox plus Bevacizumab and reolysin","genericName":"Folfox plus Bevacizumab and reolysin","slug":"folfox-plus-bevacizumab-and-reolysin","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"Intermittent PD-1 inhibitor therapy","genericName":"Intermittent PD-1 inhibitor therapy","slug":"intermittent-pd-1-inhibitor-therapy","indication":"Advanced or metastatic cancer (specific tumor types under investigation in phase 3 trials)","status":"phase_3"},{"name":"Continuous PD-1 inhibitor therapy","genericName":"Continuous PD-1 inhibitor therapy","slug":"continuous-pd-1-inhibitor-therapy","indication":"Cancer (specific tumor type under investigation in Canadian Cancer Trials Group phase 3 trial)","status":"phase_3"},{"name":"Darolutamide (BAY 1841788)","genericName":"Darolutamide (BAY 1841788)","slug":"darolutamide-bay-1841788","indication":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","status":"phase_3"},{"name":"Docetaxel and Reolysin","genericName":"Docetaxel and Reolysin","slug":"docetaxel-and-reolysin","indication":"Locally advanced or metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer","status":"phase_2"},{"name":"Folfox plus Bevacizumab","genericName":"Folfox plus Bevacizumab","slug":"folfox-plus-bevacizumab","indication":"Metastatic colorectal cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"BA3011","genericName":"BA3011","slug":"ba3011","indication":"Other","status":"phase_2"},{"name":"RP-6306","genericName":"RP-6306","slug":"rp-6306","indication":"Other","status":"phase_2"},{"name":"AdMA3","genericName":"AdMA3","slug":"adma3","indication":"Other","status":"phase_1"},{"name":"Capox","genericName":"Capox","slug":"capox","indication":"Other","status":"phase_3"},{"name":"LND101","genericName":"LND101","slug":"lnd101","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ADT","genericName":"ADT","slug":"adt","phase":"phase_3","mechanism":"ADT is an androgen deprivation therapy regimen used in prostate cancer treatment to suppress testosterone production and androgen receptor signaling.","indications":["Advanced prostate cancer","Metastatic castration-sensitive prostate cancer"],"catalyst":""},{"name":"BA3011","genericName":"BA3011","slug":"ba3011","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BA3021","genericName":"BA3021","slug":"ba3021","phase":"phase_2","mechanism":"BA3021 is a small molecule targeting the PI3K pathway.","indications":["Relapsed or refractory acute myeloid leukemia"],"catalyst":""},{"name":"Folfox plus Bevacizumab and reolysin","genericName":"Folfox plus Bevacizumab and reolysin","slug":"folfox-plus-bevacizumab-and-reolysin","phase":"phase_2","mechanism":"Folfox plus Bevacizumab and reolysin is a combination chemotherapy regimen that targets rapidly dividing cancer cells and inhibits angiogenesis.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"Intermittent PD-1 inhibitor therapy","genericName":"Intermittent PD-1 inhibitor therapy","slug":"intermittent-pd-1-inhibitor-therapy","phase":"phase_3","mechanism":"Intermittent PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells periodically, allowing the immune system to recognize and attack cancer cells in a cyclical dosing pattern.","indications":["Advanced or metastatic cancer (specific tumor types under investigation in phase 3 trials)"],"catalyst":""},{"name":"RP-6306","genericName":"RP-6306","slug":"rp-6306","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AdMA3","genericName":"AdMA3","slug":"adma3","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Capox","genericName":"Capox","slug":"capox","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Continuous PD-1 inhibitor therapy","genericName":"Continuous PD-1 inhibitor therapy","slug":"continuous-pd-1-inhibitor-therapy","phase":"phase_3","mechanism":"Continuous PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells, preventing tumor cells from suppressing anti-tumor immune responses.","indications":["Cancer (specific tumor type under investigation in Canadian Cancer Trials Group phase 3 trial)"],"catalyst":""},{"name":"Darolutamide (BAY 1841788)","genericName":"Darolutamide (BAY 1841788)","slug":"darolutamide-bay-1841788","phase":"phase_3","mechanism":"Darolutamide is a non-steroidal androgen receptor inhibitor that blocks androgen signaling in prostate cancer cells.","indications":["Non-metastatic castration-resistant prostate cancer (nmCRPC)","Metastatic hormone-sensitive prostate cancer (mHSPC)"],"catalyst":""},{"name":"Docetaxel and Reolysin","genericName":"Docetaxel and Reolysin","slug":"docetaxel-and-reolysin","phase":"phase_2","mechanism":"Docetaxel is a microtubule inhibitor that disrupts cell division, while Reolysin is a viral therapy that selectively infects and kills cancer cells.","indications":["Locally advanced or metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer"],"catalyst":""},{"name":"Folfox plus Bevacizumab","genericName":"Folfox plus Bevacizumab","slug":"folfox-plus-bevacizumab","phase":"phase_2","mechanism":"FOLFOX plus Bevacizumab inhibits angiogenesis and disrupts tumor blood supply through VEGF inhibition, while FOLFOX induces DNA damage and apoptosis in rapidly dividing cells.","indications":["Metastatic colorectal cancer"],"catalyst":""},{"name":"LND101","genericName":"LND101","slug":"lnd101","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-03","type":"trial","source":"Indian Pharma Post","summary":"Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer - Indian Pharma Post","headline":"Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOcXV6YXJtVGtHWG5XRGRVQjVxd1ZKa3lnZEp2ZXgzSGVfQmtackRsSmsyQlNUWjQ1VDJQQjhEbW1EVXMtSFNkaU1rZC05cnJGWVVwVzh3RFNMNWF4SGtjcGpUdnEwYVd6cDdqaTI5bGpYMmsxcHR3dG9od0VjbTlBeDRlYWVXNWVIQktZX2xTTUJ0Ql9pOXhjNjFUNXJIT1dhQkdRcGNORHZmLTY1dWszb3RaazcwYjQ0UktiWl9lb2ZDTXJrbm5IUnAxOA?oc=5","date":"2026-04-02","type":"trial","source":"BioPharma APAC","summary":"Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer - BioPharma APAC","headline":"Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQbUFSWkl6VVFHbC0zUmZPalNPNE5QdmJtTUtfOXBOUG9XQmZiV0hvcU1UdWg1V2JscFpEOHgwdGJ1eklxUHNUVzRlUmFwYVhoYms4V1IyYVFsUTFLVFF4d0lwakVWbklCZ0h3bGlvS3ZlRWp3alFfUTY3V0o4dThDSS1PRDNwazgtS0JYVXFCU2FWTjRKaGdGYnk2MDR5S2dtbjJGQUo3U1MycFhJX2ZZQmFfc2xTX0JKZVBpcGJkNGRwbzlKcGwxMG53bnJEYUhEU1d6RGp1WDdzWXI0TmQzcndEOWNhbHFrVGN1VFdTM3U0UGZoRGliQjY1b2hyNFFUMFhNZVJMcWY0UHVXZW4yMUJFOVJzRlVQX2hreQ?oc=5","date":"2026-04-02","type":"trial","source":"BioSpace","summary":"Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - BioSpace","headline":"Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or p","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQNms4QTgxLV9UNWhHOHFZaWxOX2tfT3JyOGNDazRyZVg1cmtvakRrQ1JZOFhGRnpneTBrVXhodVJMamRERDRZTmVQOU1YTGtFdDRPc1NZRDFXYmRheWs0eFA2WWdmSmx0ZW51bUxLTl9PMjFpQms4SjQ0bU1kZF9rNTd3?oc=5","date":"2026-04-02","type":"trial","source":"Clinical Trials Arena","summary":"Agenus enrols first patient in BATTMAN Phase III trial - Clinical Trials Arena","headline":"Agenus enrols first patient in BATTMAN Phase III trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1oR2liUC01ZUxKTndaQ0EtejlZTURpa19Ma3paQXRQRy14S2hjTVRRZFZRT0pIVHBGeE5VaUVxOFVHc3B5a3J0dTAxeHVWQzJKNnN3cnRJQ3RsQUdVR3RKVnNRNEdPamlGTnNhcVlSdXRZOG9K?oc=5","date":"2026-02-19","type":"pipeline","source":"MedPage Today","summary":"Stereotactic Radiation Better for Patients With Multiple Brain Metastases? - MedPage Today","headline":"Stereotactic Radiation Better for Patients With Multiple Brain Metastases?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQZXRxYnpFS0dEV29SVHEyMDJlV1c2cU10Y3NSNVprNF9LekJCLVZTTmpRRlQyWUk0clc5dmdhRGNNbkNpenRzdTEwNHlJUkdyRktrWFJDUDk5bTFFOElWUDZ2Q1JNSlRrUmN0endvTU5EWFJvZ1VVd0xMWEhydm10VFgyaGpvNGRyU1dBMmFOSnMtdE42RjRGS0Y5UEhsZkwwSTFza2l3?oc=5","date":"2026-01-28","type":"pipeline","source":"KHSC Kingston Health Sciences Centre","summary":"Canada’s largest cancer research tumour bank moves to new home at KHSC - KHSC Kingston Health Sciences Centre","headline":"Canada’s largest cancer research tumour bank moves to new home at KHSC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxNcUkxTEh3cjc3V3ppbEZTTjlJelFJM0R6QjBvbzRvWTRycGhhTW1mNTJVTXNzM05pVGltWDE3eTNuQUxKSFRLbEdQaXlMUnJDMXVWUlUzeEVPTEM5RS1YREMxM1M3aHdKM3NkVXlHYTRNcTE0ZU5uWl9UNHAwS2VoWS1NNXBDRUxkRzlOQUM0VEdLZnVyVFdXZjVJT0ltemhvWGNkVmtDNVc0Y2N1NGV5RDdEM2V2TzQtZVFxOU1Lem1hN0djeGNwY3BuNXUyOUFQVkVscVZYZnhsNGkzUUM1WVpTNkg3WVBEb2Q1VDFFcEUyTUF0SzBYUEVWcG4xdnlZOUphcUh4TkNJZzFKbW04?oc=5","date":"2026-01-16","type":"deal","source":"BioSpace","summary":"Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - BioSpace","headline":"Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPdjZiblVNQUZFbnBYdFEzYnA3eXhNNktfbGtyR2FTTmJhN0tPVXhJT1NHeE1pOWNhMlpzclpJUGlzQWk2amloSkRjaVpLMVowcng4Z3lhYldVd1poaUpzZ0pMOFNpcVY5Q1VGMTJ0UHVkWFg3cFozRWdfNWd0NE1DNTdmaWdwbEVaZE5jeEY5bnF1WFlzRGVDSE4wMnJjRWhTTktqaEhlZENQRVR6?oc=5","date":"2025-07-09","type":"pipeline","source":"2 Minute Medicine","summary":"Structured exercise intervention improves survival in colon cancer patients - 2 Minute Medicine","headline":"Structured exercise intervention improves survival in colon cancer patients - 2 Minute Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE45ZXRyMEVHb0owRExsSkxEQjhBeU5rcVhzLTNsYWdSNjMxaFJ5d1VsSFpXSnpKUUVQYVdRMHJNZFBSVDhiZWdoZEpiTXJ1QnMybUJuZ1F3NFlxRmZ1QUhBTg?oc=5","date":"2025-06-01","type":"pipeline","source":"NEJM","summary":"Structured Exercise after Adjuvant Chemotherapy for Colon Cancer - NEJM","headline":"Structured Exercise after Adjuvant Chemotherapy for Colon Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOTjJsd2lnLWVpbks1bEoxUjR0TFJVSzhrMXphZ1E3NFEwcFo5aWtfMlRjUXlUbmdZNW5wWWVza2FoUV92QjFYaXVNaTVadWZnMnlhNnlGOEFxVHNCQXRTVmh4ZlVDYm1aNXNITmtEWVFZN05SN1NZZ21VZjkyNUlpQTBKLVVkVktvQmc2RkhBS01DNVpuM0F6Rg?oc=5","date":"2025-06-01","type":"trial","source":"Canadian Cancer Society","summary":"World-first clinical trial confirms exercise improves survival for colon cancer - Canadian Cancer Society","headline":"World-first clinical trial confirms exercise improves survival for colon cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE0tdHZ5MEc3VUIxbGxQckhDVDRYUHF0U3d0WmtmcGlDWDBHOWl6SkZmQS11aU5DcjJpRWlyOEZzT2NkXzVCYjdEb0t5VFB5WUdWREgxQTBWZ2g3bHZzYnphV0F4N0paR1U?oc=5","date":"2025-06-01","type":"trial","source":"MedPage Today","summary":"Exercise in Cancer Trial Rivals Survival Benefit of Some Drugs - MedPage Today","headline":"Exercise in Cancer Trial Rivals Survival Benefit of Some Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxONkhpdllIelMzdTl2N1Etb3R4dF9INjl0Q0ZnQVVyc3dOS2hyLXVVOU9fNktCRzFqYlNTd19ZNnFtOUMxUXNkZUNROVp3QVBfc3RHUnYzNUs2a3pwMlVudjIxTXd2VFBLa25DSGVJV0g4X3U2RmpjZzRMakFmeFdodnd4aERPQWJ2TzByRzJRRzJPZjFUQ0tRZHA4X1UwTzM3dkNqZkNEbURJUTJ3cERj?oc=5","date":"2025-04-11","type":"trial","source":"The Globe and Mail","summary":"Trump order prompts Canadian cancer research group to scrub gender-inclusive language from U.S.-funded trials - The Globe and Mail","headline":"Trump order prompts Canadian cancer research group to scrub gender-inclusive language from U.S.-funded trials","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"phase_3":5,"phase_2":7,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}